Steroid diabetes: From mechanism to treatment?

Netherlands Journal of Medicine

Volumn 72, Issue 2, 2014, Pages 62-72

  van Raalte, D H ^a   Diamant, M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Glucocorticoids; Insulin resistance; Pancreatic islet cell dysfunction; Steroid diabetes

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; DEXAMETHASONE; GLUCAGON; GLUCOCORTICOID; GLUCOSE 6 PHOSPHATASE; INCRETIN; INSULIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PREDNISOLONE; TROGLITAZONE;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG INDUCED DISEASE; DRUG MEGADOSE; DYSLIPIDEMIA; EDEMA; FATTY LIVER; FRACTURE; GLAUCOMA; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INFECTION; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; LIVER TOXICITY; LOW DRUG DOSE; MENTAL DISEASE; METABOLIC DISORDER; OBESITY; OSTEOPOROSIS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PREVALENCE; PROTEIN METABOLISM; REVIEW; SKELETAL MUSCLE; SKELETAL MUSCLE ATROPHY; SKIN ATROPHY; STOMACH ULCER; ANIMAL; CELLULAR IMMUNITY; CHEMICALLY INDUCED; DISEASE MANAGEMENT; DRUG EFFECTS; IMMUNOLOGY; PANCREAS ISLET;

ANIMALS; DIABETES MELLITUS; DISEASE MANAGEMENT; GLUCOCORTICOIDS; HUMANS; IMMUNITY, CELLULAR; INSULIN RESISTANCE; ISLETS OF LANGERHANS;

EID: 84895781229     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009;39:81-93.
2. Zen M, Canova M, Campana C, et al. The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev. 2011;10:305-10.
3. Bierry H, Malloizel, L. Hypoglycemic après décapsulation, effets de l'injection d'adrénaline sur les animaux décapsules. Co R Soc Biol. 1908;65:232-4.
4. Long C, Katzin B, Fry, E. The adrenal cortex and carbohydrate metabolism. Endocrinology. 1940;26:309-44.
5. Reichstein T. Über bestandteile der nebennieren-rind, VI. Trennungsmethoden sowie isolierung der substanzen Fa, H und J. Helvetica Chimica Acta. 1936;19:1107-26.
6. Mason HL, Myers CS, Kendall EC. The chemistry of crystalline substances isolated from the suprarenal gland. J Biol Chem. 1936;114:613-31.
7. Hillier SG. Diamonds are forever: the cortisone legacy. J Endocrinol. 2007;195:1-6.
8. Sarett L. Partial synthesis of pregnene-4-triol-17(beta), 20(beta), 21-dione-3,11 and pregnene-4-diol-17(beta), 21-trione-3,11,20 monoacetate? J Biol Chem. 1946;162:601-31.
9. Perera GA, Pines KL, Hamilton HB, Vislocky K. Clinical and metabolic study of 11-dehydro-17-hydroxycorticosterone acetate (Kendall compound E) in hypertension, Addison's disease and diabetes mellitus. Am J Med. 1949;7:56-69.
10. Hench PS. Effect of Jaundice on Rheumatoid Arthritis. Br Med J. 1938;2:394-8.
11. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin. 1949;24:181-97.
12. Hench PK, Kendall EC, Slocumb CH, Polley HF. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med (Chic). 1950;84:545-666.
13. Bijlsma JW, van der Goes MC, Hoes JN, Jacobs JW, Buttgereit F, Kirwan J. Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy. Ann N Y Acad Sci. 2010;1193:123-6.
14. Parker BJ, Bruce IN. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus. 2007;16:387-93.
15. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372:234-45.
16. Hernandez-Rodriguez J, Cid MC, Lopez-Soto A, Espigol-Frigole G, Bosch X. Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med. 2009;169:1839-50.
17. Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med. 2008;29:533-48, ix-x.
18. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488-98.
19. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W, American Gastroenterological A. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-87.
20. Gleeson D, Heneghan MA. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611-29.
21. Tilly H, Vitolo U, Walewski J, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii78-82.
22. Harousseau JL, Dreyling M, Group EGW. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v155-7.
23. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39:1267-84.
24. Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-46.
25. Tole JW, Lieberman P. Biphasic anaphylaxis: review of incidence, clinical predictors, and observation recommendations. Immunol Allergy Clin North Am. 2007;27:309-26, viii.
26. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96:23-43.
27. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007;157:545-59.
28. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29:2728-9.
29. Blackburn D, Hux J, Mamdani M. Quantification of the Risk of Corticosteroid-induced Diabetes Mellitus Among the Elderly. J Gen Intern Med. 2002;17:717-20.
30. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154:97-101.
31. Hoes JN, van der Goes MC, van Raalte DH, et al. Glucose tolerance, insulin sensitivity and beta-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis. 2011;70:1887-94.
32. Uzu T, Harada T, Sakaguchi M, et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract. 2007;105:c54-7.
33. Fain JN. Effects of Dexamethasone and 2-Deoxy-D-Glucose on Fructose and Glucose Metabolism by Incubated Adipose Tissue. J Biol Chem. 1964;239:958-62.
34. Issekutz B, Jr., Borkow I. Effect of glucagon and glucose load on glucose kinetics, plasma FFA, and insulin in dogs treated with methylprednisolone. Metabolism. 1973;22:39-49.
35. Kaplan SA, Shimizu CS. Effects of cortisol on amino acids in skeletal muscle and plasma. Endocrinology. 1963;72:267-72.
36. Lecocq FR, Mebane D, Madison LL. The Acute Effect of Hydrocortisone on Hepatic Glucose Output and Peripheral Glucose Utilization. J Clin Invest. 1964;43:237-46.
37. Bjorntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev. 2001;2:73-86.
38. Reynolds RM, Walker BR, Syddall HE, Whorwood CB, Wood PJ, Phillips DI. Elevated plasma cortisol in glucose-intolerant men: differences in responses to glucose and habituation to venepuncture. J Clin Endocrinol Metab. 2001;86:1149-53.
39. Seckl JR. 11beta-hydroxysteroid dehydrogenases: changing glucocorticoid action. Curr Opin Pharmacol. 2004;4:597-602.
40. Morton NM, Seckl JR. 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res. 2008;36:146-64.
41. Pereira CD, Azevedo I, Monteiro R, Martins MJ. 11beta-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14:869-81.
42. Schacke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol. 2007;275:109-17.
43. Hollenberg SM, Weinberger C, Ong ES, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature. 1985;318:635-41.
44. van Lierop MJ, Alkema W, Laskewitz AJ, et al. Org 214007-0: a novel non-steroidal selective glucocorticoid receptor modulator with full anti-inflammatory properties and improved therapeutic index. PLoS One. 2012;7:e48385.
45. Barthel A, Schmoll D. Novel concepts in insulin regulation of hepatic gluconeogenesis. Am J Physiol Endocrinol Metab. 2003;285:E685-92.
46. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab. 1982;54:131-8.
47. Rooney DP, Neely RD, Cullen C, et al. The effect of cortisol on glucose/ glucose-6-phosphate cycle activity and insulin action. J Clin Endocrinol Metab. 1993;77:1180-3.
48. Wajngot A, Giacca A, Grill V, Vranic M, Efendic S. The diabetogenic effects of glucocorticoids are more pronounced in low-than in high-insulin responders. Proc Natl Acad Sci U S A. 1992;89:6035-9.
49. van Raalte DH, Brands M, van der Zijl NJ, et al. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia. 2011;54:2103-12.
50. Nielsen MF, Caumo A, Chandramouli V, et al. Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects. Am J Physiol Endocrinol Metab. 2004;286:E102-10.
51. Miyoshi H, Shulman GI, Peters EJ, Wolfe MH, Elahi D, Wolfe RR. Hormonal control of substrate cycling in humans. J Clin Invest. 1988;81:1545-55.
52. Schneiter P, Tappy L. Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. Am J Physiol. 1998;275(5 Pt 1):E806-13.
53. Wajngot A, Khan A, Giacca A, Vranic M, Efendic S. Dexamethasone increases glucose cycling, but not glucose production, in healthy subjects. Am J Physiol. 1990;259(5 Pt 1):E626-32.
54. Bollen M, Keppens S, Stalmans W. Specific features of glycogen metabolism in the liver. Biochem J. 1998;336(Pt 1):19-31.
55. Jin JY, DuBois DC, Almon RR, Jusko WJ. Receptor/gene-mediated pharmacodynamic effects of methylprednisolone on phosphoenolpyruvate carboxykinase regulation in rat liver. J Pharmacol Exp Ther. 2004;309:328-39.
56. Vander Kooi BT, Onuma H, Oeser JK, et al. The glucose-6-phosphatase catalytic subunit gene promoter contains both positive and negative glucocorticoid response elements. Mol Endocrinol. 2005;19:3001-22.
57. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol. 2007;275:43-61.
58. Kraus-Friedmann N. Hormonal regulation of hepatic gluconeogenesis. Physiol Rev. 1984;64:170-259.
59. Dirlewanger M, Schneiter PH, Paquot N, Jequier E, Rey V, Tappy L. Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr. 2000;19:29-34.
60. Saad MJ, Folli F, Kahn JA, Kahn CR. Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest. 1993;92:2065-72.
61. Zinker B, Mika A, Nguyen P, et al. Liver-selective glucocorticoid receptor antagonism decreases glucose production and increases glucose disposal, ameliorating insulin resistance. Metabolism. 2007;56:380-7.
62. Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol. 2008;197:189-204.
63. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes. 1981;30:1000-7.
64. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799-806.
65. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H. Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia. 1997;40:1439-48.
66. Larsson H, Ahren B. Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. Diabetologia. 1999;42:936-43.
67. van Raalte DH, Kwa KA, van Genugten RE, et al. Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance? Metabolism. 2013;62:568-77.
68. Henriksen JE, Alford F, Vaag A, Handberg A, Beck-Nielsen H. Intracellular skeletal muscle glucose metabolism is differentially altered by dexamethasone treatment of normoglycemic relatives of type 2 diabetic patients. Metabolism. 1999;48:1128-35.
69. Khaleeli AA, Edwards RH, Gohil K, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf). 1983;18:155-66.
70. Ruzzin J, Wagman AS, Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia. 2005;48:2119-30.
71. Lofberg E, Gutierrez A, Wernerman J, et al. Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. Eur J Clin Invest. 2002;32:345-53.
72. Short KR, Bigelow ML, Nair KS. Short-term prednisone use antagonizes insulin's anabolic effect on muscle protein and glucose metabolism in young healthy people. Am J Physiol Endocrinol Metab. 2009;297:E1260-8.
73. Krebs M, Krssak M, Bernroider E, et al. Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. Diabetes. 2002;51:599-605.
74. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord. 2003;27(Suppl 3):S6-11.
75. Barrett EJ, Eggleston EM, Inyard AC, et al. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia. 2009;52:752-64.
76. Kubota T, Kubota N, Kumagai H, et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab. 2011;13:294-307.
77. van Raalte DH, Diamant M, Ouwens DM, et al. Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: a randomised controlled trial. Diabetologia. 2013;56:2383-91.
78. McMahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev. 1988;4:17-30.
79. Hamel FG, Fawcett J, Bennett RG, Duckworth WC. Control of proteolysis: hormones, nutrients, and the changing role of the proteasome. Curr Opin Clin Nutr Metab Care. 2004;7:255-8.
80. Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism. 2011;60:1500-10.
81. Rockall AG, Sohaib SA, Evans D, et al. Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome. Eur J Endocrinol. 2003;149:561-7.
82. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11:11-8.
83. Turnbow MA, Keller SR, Rice KM, Garner CW. Dexamethasone down-regulation of insulin receptor substrate-1 in 3T3-L1 adipocytes. J Biol Chem. 1994;269:2516-20.
84. Dimitriadis G, Mitrou P, Lambadiari V, Maratou E, Raptis SA. Insulin effects in muscle and adipose tissue. Diabetes Res Clin Pract. 2011;93(Suppl 1):S52-9.
85. Abel ED, Peroni O, Kim JK, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 2001;409:729-33.
86. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46:1594-603.
87. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85-97.
88. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003;46:3-19.
89. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993;42:1663-72.
90. van Raalte DH, Diamant M. Glucolipotoxicity and beta cells in type 2 diabetes mellitus: Target for durable therapy? Diabetes Res Clin Pract. 2011;93(Suppl 1):S37-46.
91. Ranta F, Avram D, Berchtold S, et al. Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes. 2006;55:1380-90.
92. Linssen MM, van Raalte DH, Toonen EJ, et al. Prednisolone-induced beta cell dysfunction is associated with impaired endoplasmic reticulum homeostasis in INS-1E cells. Cell Signal. 2011;23:1708-15.
93. Davani B, Portwood N, Bryzgalova G, et al. Aged transgenic mice with increased glucocorticoid sensitivity in pancreatic beta-cells develop diabetes. Diabetes. 2004;53(Suppl 1):S51-9.
94. Kalhan SC, Adam PA. Inhibitory effect of prednisone on insulin secretion in man: model for duplication of blood glucose concentration. J Clin Endocrinol Metab. 1975;41:600-10.
95. van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care. 2011;34:412-7.
96. van Raalte DH, Nofrate V, Bunck MC, et al. Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men. Eur J Endocrinol. 2010;162:729-35.
97. Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab. 2010;95:3309-17.
98. Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK. Impaired Incretin-Induced Amplification of Insulin Secretion after Glucose Homeostatic Dysregulation in Healthy Subjects. J Clin Endocrinol Metab. 2012;97:1363-70.
99. Besse C, Nicod N, Tappy L. Changes in insulin secretion and glucose metabolism induced by dexamethasone in lean and obese females. Obes Res. 2005;13:306-11.
100. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D, Jr. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest. 1984;74:1318-28.
101. van Raalte DH, van Leeuwen N, Simonis-Bik AMC, et al. Glucocorticoid Receptor Gene Polymorphisms are Associated with Reduced First-phase Glucose-Stimulated Insulin Secretion and Disposition Index in Women, but not in Men. Diabet Med. 2012;29:e211-6.
102. Gromada J, Franklin I, Wollheim CB. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev. 2007;28:84-116.
103. Wise JK, Hendler R, Felig P. Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. J Clin Invest. 1973;52:2774-82.
104. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002;122:531-44.
105. van Genugten RE, van Raalte DH, Diamant M. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. Diabetes Res Clin Pract. 2009;86(Suppl 1):S26-34.
106. van Genugten RE, van Raalte DH, Diamant M. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes Obes Metab. 2012;14:101-11.
107. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes. 2010;59:1117-25.
108. Zhang R, Packard BA, Tauchi M, D'Alessio DA, Herman JP. Glucocorticoid regulation of preproglucagon transcription and RNA stability during stress. Proc Natl Acad Sci U S A. 2009;106:5913-8.
109. Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. J Clin Endocrinol Metab. 2011;96:447-53.
110. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab. 2011;96:1789-96.
111. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15:469-74.
112. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88:5593-602.
113. Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ. Adverse events of low-to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68:1833-8.
114. Kwon S, Hermayer KL. Glucocorticoid-induced hyperglycemia. Am J Med Sci. 2013;345:274-7.
115. Morita H, Oki Y, Ito T, Ohishi H, Suzuki S, Nakamura H. Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM. Diabetes Care. 2001;24:788-9.
116. Willi SM, Kennedy A, Wallace P, Ganaway E, Rogers NL, Garvey WT. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin. Diabetes. 2002;51:2895-902.
117. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256-63.
118. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168:820-5.
119. Cervera A, Wajcberg E, Sriwijitkamol A, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008;294:E846-52.
120. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl 2):S279-84.
121. Ritzel RA, Kleine N, Holst JJ, Willms B, Schmiegel W, Nauck MA. Preserved GLP-1 effects in a diabetic patient with Cushing's disease. Exp Clin Endocrinol Diabetes. 2007;115:146-50.
122. Matsuo K, Nambu T, Matsuda Y, et al. Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy. Intern Med. 2013;52:89-95.
123. http://clinicaltrials.gov/ct2/show/NCT00721552?term=SPHINX&rank=1.
124. den Uyl D, van Raalte DH, Nurmohamed MT, et al. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: Diabetogenic effects and inflammation reduction on the balance. Arthritis Rheum. 2012;64:639-46.